サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747789

ヒトパピローマウイルス（HPV）ワクチンの世界市場

Human Papillomavirus (HPV) Vaccines

出版日
ページ情報
英文 279 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.42円
ヒトパピローマウイルス（HPV）ワクチンの世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 279 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヒトパピローマウイルス（HPV）ワクチンの世界市場は2030年までに97億米ドルに達する見込み

2024年に55億米ドルと推定されるヒトパピローマウイルス（HPV）ワクチンの世界市場は、分析期間2024-2030年にCAGR 9.9%で成長し、2030年には97億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである4価ワクチンは、CAGR 9.5%を記録し、分析期間終了時には58億米ドルに達すると予測されます。非原子価ワクチン分野の成長率は、分析期間中CAGR 11.3%と推定されます。

米国市場は15億米ドルと推定、中国はCAGR13.4％で成長予測

米国のヒトパピローマウイルス（HPV）ワクチン市場は、2024年には15億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに20億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.1％と8.7％と予測されています。欧州では、ドイツがCAGR 7.8%で成長すると予測されています。

世界のヒトパピローマウイルス（HPV）ワクチン市場- 主要動向と促進要因のまとめ

なぜHPVワクチンは世界のウイルス関連がんの予防に不可欠なのか？

ヒトパピローマウイルス（HPV）ワクチンは、子宮頸がん、口腔咽頭がん、肛門がん、性器がんなど、HPV関連がんの予防において中心的な役割を果たしています。200種類以上のHPVが同定され、HPV-16やHPV-18などの高リスク株が子宮頸がん患者の大部分を占めていることから、予防接種の普及は世界のがん予防戦略の要と考えられています。これらのワクチンは、免疫系を刺激して標的ウイルス株に対する抗体を産生させ、持続的な感染や前がん病変に対する長期的な防御を提供します。

WHOやCDCを含む世界の保健当局は、公衆衛生上の予防策として、特に性行為開始前の青少年へのHPVワクチン接種を推奨しています。オーストラリアや英国のような国々で子宮頸がん罹患率を減少させる国家的な予防接種プログラムの成功は、公衆衛生の脅威としての子宮頸がんを撲滅するというWHOの目標達成に向けた世界の機運を強めています。いくつかの地域で意識が高まり、ワクチン接種へのためらいが減少するにつれ、HPVワクチンの市場は先進国、新興経済諸国ともに着実に拡大しています。

ワクチンの製剤と流通戦略はどのように進化しているのか？

HPVワクチンは、2価ワクチン（HPV-16および18を対象）から4価ワクチン（HPV-6および11に対する防御を追加）へと進化し、現在では子宮頸がんの最大90％の原因となっているものを含む9種類のHPV株を防御する非2価ワクチンへと進化しています。このような幅広いスペクトラムを持つワクチンは接種範囲が広く、今後のワクチン調達や予防接種プログラムの主流になると予想されます。組換えワクチン製造とアジュバント・システムにおける絶え間ない技術革新により、免疫反応と予防期間が向上しています。

学校単位の予防接種プログラム、性別にとらわれないキャンペーン、国の小児予防接種スケジュールとの統合などにより、ワクチンの流通は最適化されています。コールドチェーン・インフラの進歩は、政府、NGO、ワクチン製造業者間のパートナーシップと相まって、中低所得国でのアクセスを向上させています。また、費用対効果が高く、ロジスティクス的にも簡便な代替手段として、単回接種レジメンの研究も進められており、ワクチン接種のプロトコルを再構築し、世界の普及を拡大する可能性のある有望な結果が得られています。

どこで接種率が上昇し、どのような障壁が残っているのか？

北米、欧州、アジア太平洋の一部では、一般市民の意識、ヘルスケアのインフラ、政策的支援が強く、ワクチン接種率が上昇しています。特に、男性のHPVに関連する頭頸部がんの予防を優先している国では、性別にとらわれないワクチン接種戦略が支持を集めています。ラテンアメリカとサハラ以南のアフリカは、HPVの負担が大きいにもかかわらず、供給制限、ヘルスケアへのアクセス格差、文化的抵抗などの課題に直面しています。

特に保守的な地域や資源に乏しい地域では、誤った情報、ワクチン接種へのためらい、一貫性のない公衆衛生メッセージなどが障壁となっています。また、成人向けの予防接種プログラムが限られていることや、経済的な問題も、より広範な市場への浸透を妨げています。しかし、ワクチン同盟（Gavi）のような組織とのパートナーシップにより、段階的価格設定やドナー資金によるイニシアチブを通じて、供給の不公平や経済的障壁に積極的に取り組んでいます。これらの問題が緩和されれば、特に高負担地域において、市場の成長は加速すると予想されます。

HPVワクチン市場の成長はいくつかの要因によって牽引される...

HPV関連がんを予防するための世界の取り組みの増加、予防接種プログラムの拡大、広域スペクトルワクチン製剤の入手可能性などが市場の成長を牽引しています。WHOの子宮頸がん撲滅戦略とともに、女性の健康とがん予防に対する公衆衛生投資の増加が需要を喚起しています。ワクチン接種プログラムに男児が組み込まれ、HPVに関連する頭頸部がんの発生率が高まっていることが、対応可能な市場をさらに拡大しています。

ワクチンの有効性、長期予防データ、単回投与レジメンの可能性に関する科学的進歩が、より広範な実施を後押ししています。さらに、政府、ワクチン開発者、保健機関間のパートナーシップは、特に新興国市場において、調達、教育、インフラを強化しています。デジタル・ヘルス・プラットフォームとmヘルス・キャンペーンも、アウトリーチと記録の追跡を改善し、ワクチン摂取を増加させています。これらの動向を総合すると、HPVワクチンは世界の疾病予防における重要なツールであり、より広範なワクチン市場の中でダイナミックなセグメントとして強化されています。

セグメント

タイプ（4価、非5価、2価）;流通チャネル（病院・小売薬局、政府系サプライヤー、その他流通チャネル）

調査対象企業の例（注目の42社）

  • Barinthus Biotherapeutics
  • Bharat Biotech
  • BioNTech SE
  • CanSino Biologics Inc.
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company
  • Valneva SE
  • Vaxart, Inc.
  • Walvax Biotechnology Co., Ltd.
  • Wantai BioPharm
  • Xiamen Innovax Biotech Co., Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35196

Global Human Papillomavirus (HPV) Vaccines Market to Reach US$9.7 Billion by 2030

The global market for Human Papillomavirus (HPV) Vaccines estimated at US$5.5 Billion in the year 2024, is expected to reach US$9.7 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Tetravalent Vaccines, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$5.8 Billion by the end of the analysis period. Growth in the Nonavalent Vaccines segment is estimated at 11.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 13.4% CAGR

The Human Papillomavirus (HPV) Vaccines market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 13.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Global Human Papillomavirus (HPV) Vaccines Market - Key Trends & Drivers Summarized

Why Are HPV Vaccines Critical in Preventing Virus-Linked Cancers Worldwide?

Human papillomavirus (HPV) vaccines play a central role in the prevention of HPV-related cancers, including cervical, oropharyngeal, anal, and genital cancers. With over 200 types of HPV identified and high-risk strains such as HPV-16 and HPV-18 accounting for the majority of cervical cancer cases, widespread immunization is viewed as a cornerstone of global cancer prevention strategies. These vaccines stimulate the immune system to develop antibodies against targeted viral strains, offering long-term protection against persistent infections and precancerous lesions.

Global health authorities, including the WHO and CDC, recommend HPV vaccination for adolescents, particularly before the onset of sexual activity, as a preventive public health measure. The success of national immunization programs in reducing cervical cancer incidence in countries like Australia and the UK has strengthened global momentum toward achieving the WHO’s goal of eliminating cervical cancer as a public health threat. As awareness increases and vaccine hesitancy declines in several regions, the market for HPV vaccines is steadily expanding across both developed and emerging economies.

How Are Vaccine Formulations and Distribution Strategies Evolving?

HPV vaccines have progressed from bivalent formulations (targeting HPV-16 and 18) to quadrivalent (adding protection against HPV-6 and 11) and now to nonavalent vaccines, which protect against nine HPV strains, including those responsible for up to 90% of cervical cancers. These broader-spectrum vaccines offer greater coverage and are expected to dominate future procurement and immunization programs. Continuous innovation in recombinant vaccine production and adjuvant systems is enhancing immune response and duration of protection.

Distribution is being optimized through school-based vaccination programs, gender-neutral campaigns, and integration with national childhood immunization schedules. Advances in cold-chain infrastructure, coupled with partnerships between governments, NGOs, and vaccine manufacturers, are improving access in low- and middle-income countries. Single-dose regimens are also under investigation as a cost-effective and logistically simpler alternative, with promising results that may reshape vaccination protocol and broaden global coverage.

Where Is Uptake Increasing and What Barriers Remain?

Vaccination uptake is rising in North America, Europe, and parts of Asia-Pacific where public awareness, healthcare infrastructure, and policy support are strong. Gender-neutral vaccination strategies are gaining traction, particularly in countries prioritizing the prevention of head and neck cancers linked to HPV in males. Latin America and Sub-Saharan Africa, despite high HPV burden, still face challenges including supply limitations, healthcare access gaps, and cultural resistance.

Barriers include misinformation, vaccine hesitancy, and inconsistent public health messaging, particularly in conservative or resource-constrained regions. Limited adult vaccination programs and affordability issues also hamper broader market penetration. However, partnerships with organizations such as Gavi, the Vaccine Alliance, are actively addressing supply inequities and financial barriers through tiered pricing and donor-funded initiatives. As these issues are mitigated, market growth is expected to accelerate, particularly in high-burden regions.

The Growth in the HPV Vaccines Market Is Driven by Several Factors…

It is driven by increasing global efforts to prevent HPV-related cancers, expansion of immunization programs, and the availability of broad-spectrum vaccine formulations. Rising public health investment in women’s health and cancer prevention, along with WHO’s cervical cancer elimination strategy, is catalyzing demand. The inclusion of boys in vaccination programs and growing incidence of HPV-linked head and neck cancers are further expanding the addressable market.

Scientific progress in vaccine efficacy, long-term protection data, and potential single-dose regimens is supporting broader implementation. Additionally, partnerships between governments, vaccine developers, and health organizations are enhancing procurement, education, and infrastructure-especially in emerging markets. Digital health platforms and mHealth campaigns are also improving outreach and record tracking, increasing vaccine uptake. Collectively, these trends are reinforcing HPV vaccines as a critical tool in global disease prevention and a dynamic segment within the broader vaccines market.

SCOPE OF STUDY:

The report analyzes the Human Papillomavirus (HPV) Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Tetravalent, Nonavalent, Bivalent); Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Barinthus Biotherapeutics
  • Bharat Biotech
  • BioNTech SE
  • CanSino Biologics Inc.
  • GlaxoSmithKline plc
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company
  • Valneva SE
  • Vaxart, Inc.
  • Walvax Biotechnology Co., Ltd.
  • Wantai BioPharm
  • Xiamen Innovax Biotech Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Human Papillomavirus (HPV) Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Awareness of HPV-Linked Cervical and Oropharyngeal Cancers Drives Preventive Vaccination Uptake
    • Inclusion of HPV Vaccines in National Immunization Programs Expands Coverage Across Adolescents and Young Adults
    • WHO and GAVI Support for HPV Vaccine Rollout in Low-Income Countries Strengthens Public Health Impact
    • Expansion of Gender-Neutral Vaccination Policies Fuels Demand Across Male and Female Populations
    • Technological Advancements in Vaccine Formulations Improve Long-Term Efficacy and Broaden Strain Coverage
    • Increased School-Based Immunization Drives High Compliance Rates in Developed and Emerging Regions
    • Public-Private Partnerships and Awareness Campaigns Boost Community-Level Vaccine Acceptance
    • Improved Cold Chain Infrastructure and Global Procurement Facilitate Distribution to Remote Areas
    • Rising Incidence of HPV-Associated Head and Neck Cancers Spurs Broader Advocacy for Adult Vaccination
    • Growing Market Entry of Biosimilar and Region-Specific HPV Vaccines Enhances Accessibility and Affordability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Human Papillomavirus (HPV) Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Human Papillomavirus (HPV) Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Tetravalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Tetravalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Tetravalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Nonavalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Nonavalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Nonavalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Bivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Bivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Bivalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospital & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Government Suppliers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Government Suppliers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Government Suppliers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Human Papillomavirus (HPV) Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Human Papillomavirus (HPV) Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Human Papillomavirus (HPV) Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Human Papillomavirus (HPV) Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Human Papillomavirus (HPV) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Human Papillomavirus (HPV) Vaccines by Type - Tetravalent, Nonavalent and Bivalent Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Type - Percentage Breakdown of Value Sales for Tetravalent, Nonavalent and Bivalent for the Years 2015, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Human Papillomavirus (HPV) Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION